BioTiss is a biotechnology company with the mission of improving efficacy of allograft tissue by applying high-tech refinement according to the need of patients. Smart grafts shall improve the outcome and reduce treatment time of cases with major tissue defects. Its lead product OSTEOmycin® is already successfully used in septic orthopaedic surgery.

Through this partnership, Leader Biomedical has combined its proprietary supercritical CO2 platform, eCOO® Technology with BioTiss’s OSTEOmycin®, resulting in safe, efficient, and antibiotic-impregnated allografts, catering to the infection care market.